Extraordinary General Meeting 2019

Västra Trädgårdsgatan 15, Stockholm, Sweden.

Upcoming events

Webcast -- update from the ODAC meeting, Sep 22

14:00 CET

September 23, 2022, the Oncologic Drugs Advisory Committee (ODAC), of the US Food and Drug Administration (FDA), has finalized the discussion on the benefit-risk profile of Pepaxto® (melphalan flufenamide, also called melflufen). A majority of the panel considered that OCEAN did not confirm a favorable benefit-risk profile in the current indicated patient population.

Silent Period

-

Silent Period

-

Year-end report 2022

08:00 CET